期刊
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
卷 11, 期 8, 页码 1303-1315出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.2015.1052404
关键词
anti-inflammatory; cancer therapy; dendrimer; ligand; prodrug; theranostics
资金
- Japan Society for the Promotion of Science (JSPS) [26410227]
- Grants-in-Aid for Scientific Research [26410227] Funding Source: KAKEN
Introduction: Dendrimers are synthetic macromolecules with well-defined structures bearing a wide variety of functional groups on their periphery. These groups can be used to conjugate bioactive molecules such as drugs, ligands and imaging agents. Dendrimer prodrugs can be used to improve the water solubility and pharmacokinetic properties of the corresponding free drugs. Areas covered: This article summarizes preclinical studies pertaining to the use of drug-dendrimer conjugates as dendrimer prodrugs for the treatments of various diseases, including cancer and inflammatory diseases. A wide range of anticancer drugs have been conjugated to dendrimers via biodegradable linkers. The side effects of the parent drugs can be markedly reduced using dendrimer prodrugs, with some drugs showing improved efficacy. Antiinflammatory agents have also been conjugated to dendrimers and used to treat a number of inflammatory diseases. Expert opinion: Drug-dendrimer conjugates are preferable to drug-dendrimer complexes, where the use of degradable linkers is critical to the release of the drug. Polyethylene glycol and/or ligands can be added to a dendrimer prodrug, which is useful for the targeting of affected tissues. Imaging probes can also be incorporated into dendrimer prodrugs for the simultaneous delivery of therapeutic and diagnostic agents as 'theranostics.'
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据